Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies.

Elemento

Click for External Resource*

https://www.ncbi.nlm.nih.gov/pubmed/26766162

Click to read full article*

https://onlinelibrary.wiley.com/doi/full/10.1111/vox.12376

The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.

Files for Download

Geisen_et_al-2016-Vox_Sanguinis.pdf

Item Type

Publicación

Terms of Use

By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.

Visor de documentos

Share this page:

Facebook Twitter e-mail

Was this resource helpful?

Título

Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies.

Materia

Research

Descripción

Ebola virus disease is a public health emergency of international concern, and enormous efforts are being made in the development of vaccines and therapies.

Autor

Fecha

2016-05

Tipo

Publication

Citación

Geisen, C., G. Kann, T. Strecker, T. Wolf, G. Schüttfort, M. van Kraaij, S. MacLennan, S. Rummler, C. Weinigel, M. Eickmann, S. K. Fehling, V. Krähling, C. Seidl, E. Seifried, M. Schmidt, and R. Schäfer. 2016. "Pathogen-reduced Ebola virus convalescent plasma: first steps towards standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies." Vox Sanguinis 110 (4):329-35.

Resumen

Abstract

Background

Ebola virus disease is a public health emergency of international concern, and enormous efforts are being made in the development of vaccines and therapies. Ebola virus convalescent plasma is a promising anti‐infective treatment of Ebola virus disease. Therefore, we developed and implemented a pathogen‐reduced Ebola virus convalescent plasma concept in accordance with national, European and global regulatory framework.

Materials and Methods

Ebola virus convalescent plasma manufacture and distribution was managed by a collection centre, two medical centres and an expert group from the European Blood Alliance. Ebola virus convalescent plasma was collected twice with an interval of 61 days from a donor recovering from Ebola virus disease in Germany. After pathogen reduction, the plasma was analysed for Ebola virus‐specific immunoglobulin G (IgG) antibodies and its Ebola virus neutralizing activity.

Results

Convalescent plasma could be collected without adverse events. Anti‐Ebola virus IgG titres and Ebola‐specific neutralizing antibodies in convalescent plasma were only slightly reduced after pathogen reduction treatment with S59 amotosalen/UVA. A patient in Italy with Ebola virus disease was treated with convalescent plasma without apparent adverse effects.

Discussion

As proof of principle, we describe a concept and practical implementation of pathogen‐reduced Ebola virus convalescent plasma manufacture, quality control and its clinical application to an Ebola virus disease patient.